AbCellera Biologics Inc.
ABCL
$2.39
$0.052.14%
| Weiss Ratings | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.87 | |||
| Price History | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.25% | |||
| 30-Day Total Return | -32.29% | |||
| 60-Day Total Return | -16.14% | |||
| 90-Day Total Return | -14.03% | |||
| Year to Date Total Return | -21.12% | |||
| 1-Year Total Return | -50.92% | |||
| 2-Year Total Return | -70.49% | |||
| 3-Year Total Return | -71.14% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -53.37% | |||
| 52-Week Low % Change | 8.64% | |||
| Price | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.13 | |||
| 52-Week Low Price | $2.20 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 712.19M | |||
| Enterprise Value | 151.94M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.56 | |||
| Earnings Per Share Growth | 7.56% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 24.51 | |||
| Price/Book (Q) | 0.67 | |||
| Enterprise Value/Revenue (TTM) | 5.27 | |||
| Price | $2.39 | |||
| Enterprise Value/EBITDA (TTM) | -0.80 | |||
| Enterprise Value/EBIT | -0.54 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 295.52M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 559 9005 | |||
| Address | 2215 Yukon Street Vancouver, BC V5Y 0A1 | |||
| Website | www.abcellera.com | |||
| Country | Canada | |||
| Year Founded | 2012 | |||
| Profitability | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -980.66% | |||
| Profit Margin | -564.80% | |||
| Management Effectiveness | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.41% | |||
| Return on Equity | -- | |||
| Income Statement | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 28.83M | |||
| Total Revenue (TTM) | 28.83M | |||
| Revenue Per Share | $0.10 | |||
| Gross Profit (TTM) | -138.43M | |||
| EBITDA (TTM) | -189.77M | |||
| EBIT (TTM) | -282.77M | |||
| Net Income (TTM) | -162.86M | |||
| Net Income Avl. to Common (TTM) | -162.86M | |||
| Total Revenue Growth (Q YOY) | -44.98% | |||
| Earnings Growth (Q YOY) | 27.44% | |||
| EPS Diluted (TTM) | -0.56 | |||
| EPS Diluted Growth (Q YOY) | 31.80% | |||
| Balance Sheet | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 625.61M | |||
| Cash Per Share (Q) | $2.12 | |||
| Total Current Assets (Q) | 751.37M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.06B | |||
| Current Ratio (Q) | 9.807 | |||
| Book Value Per Share (Q) | $3.57 | |||
| Total Assets (Q) | 1.36B | |||
| Total Current Liabilities (Q) | 76.61M | |||
| Total Debt (Q) | 65.36M | |||
| Total Liabilities (Q) | 304.47M | |||
| Total Common Equity (Q) | 1.06B | |||
| Cash Flow | ABCL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 121.41M | |||
| Cash from Financing (TTM) | 12.77M | |||
| Net Change in Cash (TTM) | 23.01M | |||
| Levered Free Cash Flow (TTM) | -177.77M | |||
| Cash from Operations (TTM) | -108.56M | |||
